Project Grant R01HL182733
Award Date 9/1/26
Completion Date 6/30/31
Dollars Obligated $701K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Baylor College of Medicine $625,035 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support research into the molecular mechanisms of mitochondrial calcium exchange in the heart. The research addresses mitochondrial calcium overload, which triggers cell death and tissue damage during ischemia-reperfusion injury—a secondary phase of cardiac damage that can account for up to 50 percent of final infarct...
- The National Heart, Lung, and Blood Institute awarded Baylor College of Medicine $158,892 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to examine the impact of DNMT3A protein reduction on normal and clonal hematopoiesis. The research investigates mechanisms by which somatic DNMT3A mutations drive clonal hematopoiesis—the clonal expansion of mutated hematopoietic stem and progenitor cells—which accelerates with age and increases the risk of hematologic...
- The National Heart, Lung, and Blood Institute awarded Baylor College of Medicine $643,349 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 17, 2026, to investigate the role of gasdermin D (GSDMD) inhibition in reducing inflammation-related atrial fibrillation risk associated with clonal hematopoiesis and aging. The research employs bone marrow transplantation, deep cardiac phenotyping, single-cell transcriptomics, and genetic analyses to elucidate how clonal...
- The National Heart, Lung, and Blood Institute awarded Beckman Research Institute of The City of Hope $697,806 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop integrative machine learning approaches that decode cardiomyocyte subtype dynamics in heart failure progression. The research addresses molecular mechanisms governing the transition from adaptive cardiac hypertrophy to pathological heart failure. The recipient will generate and analyze...
- The National Heart, Lung, and Blood Institute awarded J. David Gladstone Institutes $1,585,727 on September 12, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate epigenomic mechanisms of cardiac fibrosis and heart failure. The project tests the hypothesis that the transcriptional regulator Meox1 functions as a key driver of fibroblast activation, myocardial fibrosis, and heart failure pathogenesis, leveraging novel genetic mouse models, cell lines, and...
- The National Institutes of Health National Heart Lung and Blood Institute awarded The Methodist Hospital Research Institute $789,693 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837, R01HL172902) to investigate alternative polyadenylation regulation in cardiac fibrosis. The research examines how depletion of the alternative polyadenylation regulator NUDT21 drives three-prime untranslated region shortening of profibrotic transcripts and contributes to...
- The National Heart, Lung, and Blood Institute awarded the Trustees of Boston University $849,790 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to decode regulatory variants in cardiovascular disease through functional annotation of non-coding variants associated with CVD. The recipient will characterize non-coding regulatory variants and their mechanisms using high-throughput experimental approaches in human cardiomyocytes. Aim 1 encompasses biophysical...
- Federal Grant Award Summary Baylor College of Medicine received a $673,598 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 15, 2025, with a completion date of June 30, 2029. The project, "Cardiomyocyte-Fibroblast Signaling in Atrial Fibrillation," delivers basic and translational research services investigating molecular mechanisms underlying atrial fibrillation (AF), a...
- The National Heart, Lung, and Blood Institute, National Institutes of Health awarded Baylor College of Medicine $256,682 on September 23, 2025, for research on endothelial de novo nucleotide synthesis in atherosclerosis under the Cardiovascular Diseases Research program (CFDA 93.837). The project investigates how de novo purine and pyrimidine synthesis in endothelial cells protects against atherosclerotic lesion formation in response to disturbed flow and other atherosclerotic risk factors....
- The National Heart, Lung, and Blood Institute awarded The Broad Institute, Inc. $173,825 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct functional genomics research investigating gene regulatory networks in cardiac fibrosis. The award funds research to identify and characterize the transcriptional regulators that promote and maintain the activated cardiac fibroblast cell state in heart failure patients. Cardiac fibrosis—the excessive deposition of...